News & Events

Press releases

Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study

READ MORE...

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections

READ MORE...

Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent

READ MORE...

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

READ MORE...

Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts

READ MORE...

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

READ MORE...

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

READ MORE...

Pneumagen Announces Appointment of John Beadle as Non-Executive Director

READ MORE...

Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022

READ MORE...

Event information

J.P. Morgan Healthcare Conference and Biotech Showcase I January 8th – 11th 2024

READ MORE...

Jefferies London Healthcare Conference I November 14th – 16th 2023

READ MORE...

BARDA Industry Day in Washington I November 13th-14th 2023

READ MORE...

BIO-Europe in Munich I November 6th-8th 2023

READ MORE...

Bio€quity Europe in Dublin | May 14th – 16th 2023

READ MORE...

BioTrinity in London | April 25 – 26th 2023

READ MORE...

Biotech Showcase / JPM Week | January 9th – 11th 2023

READ MORE...

Jefferies London Healthcare Conference | November 15th – 17th 2022

READ MORE...

BIO-Europe in Leipzig | October 24th – 26th 2022

READ MORE...